Literature DB >> 33649421

Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.

Philippe Thuillier1,2, David Bourhis3,4, Jean Philippe Metges5, Romain Le Pennec3,4, Karim Amrane6, Ulrike Schick6, Frédérique Blanc-Beguin3,4, Simon Hennebicq3,4, Pierre-Yves Salaun3,4, Véronique Kerlan7,3, Nicolas Karakatsanis8, Ronan Abgral3,4.   

Abstract

To present the feasibility of a dynamic whole-body (DWB) 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors (WD-NETs). Sixty-one patients who underwent a DWB 68Ga-DOTATOC-PET/CT for a histologically proven/highly suspected WD-NET were prospectively included. The acquisition consisted in single-bed dynamic acquisition centered on the heart, followed by the DWB and static acquisitions. For liver, spleen and tumor (1-5/patient), Ki values (in ml/min/100 ml) were calculated according to Patlak's analysis and tumor-to-liver (TLR-Ki) and tumor-to-spleen ratios (TSR-Ki) were recorded. Ki-based parameters were compared to static parameters (SUVmax/SUVmean, TLR/TSRmean, according to liver/spleen SUVmean), in the whole-cohort and according to the PET system (analog/digital). A correlation analysis between SUVmean/Ki was performed using linear and non-linear regressions. Ki-liver was not influenced by the PET system used, unlike SUVmax/SUVmean. The regression analysis showed a non-linear relation between Ki/SUVmean (R2 = 0.55,0.68 and 0.71 for liver, spleen and tumor uptake, respectively) and a linear relation between TLRmean/TLR-Ki (R2 = 0.75). These results were not affected by the PET system, on the contrary of the relation between TSRmean/TSR-Ki (R2 = 0.94 and 0.73 using linear and non-linear regressions in digital and analog systems, respectively). Our study is the first showing the feasibility of a DWB 68Ga-DOTATOC-PET/CT acquisition in WD-NETs.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33649421      PMCID: PMC7921579          DOI: 10.1038/s41598-021-83965-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  33 in total

1.  68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Authors:  Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 2.  The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.

Authors:  Martin Barrio; Johannes Czernin; Stefano Fanti; Valentina Ambrosini; Ina Binse; Lin Du; Matthias Eiber; Ken Herrmann; Wolfgang P Fendler
Journal:  J Nucl Med       Date:  2017-01-12       Impact factor: 10.057

3.  Noninvasive quantification of the cerebral metabolic rate for glucose using positron emission tomography, 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function.

Authors:  K Chen; D Bandy; E Reiman; S C Huang; M Lawson; D Feng; L S Yun; A Palant
Journal:  J Cereb Blood Flow Metab       Date:  1998-07       Impact factor: 6.200

4.  SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.

Authors:  C Kratochwil; M Stefanova; E Mavriopoulou; T Holland-Letz; A Dimitrakopoulou-Strauss; A Afshar-Oromieh; W Mier; U Haberkorn; F L Giesel
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

5.  68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Authors:  Michael Gabriel; Andreas Oberauer; Georg Dobrozemsky; Clemens Decristoforo; Daniel Putzer; Dorota Kendler; Christian Uprimny; Peter Kovacs; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

6.  (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

Authors:  Ingrid H Olsen; Seppo W Langer; Birgitte H Federspiel; Jytte Oxbøl; Annika Loft; Anne Kiil Berthelsen; Jann Mortensen; Peter Oturai; Ulrich Knigge; Andreas Kjær
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28

7.  Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation.

Authors:  Nicolas A Karakatsanis; Martin A Lodge; Y Zhou; Richard L Wahl; Arman Rahmim
Journal:  Phys Med Biol       Date:  2013-09-30       Impact factor: 3.609

8.  Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application.

Authors:  Nicolas A Karakatsanis; Martin A Lodge; Abdel K Tahari; Y Zhou; Richard L Wahl; Arman Rahmim
Journal:  Phys Med Biol       Date:  2013-09-30       Impact factor: 3.609

9.  Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET.

Authors:  Nicolas A Karakatsanis; Yun Zhou; Martin A Lodge; Michael E Casey; Richard L Wahl; Habib Zaidi; Arman Rahmim
Journal:  Phys Med Biol       Date:  2015-10-28       Impact factor: 3.609

10.  Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.

Authors:  Martin H Cherk; Grace Kong; Rodney J Hicks; Michael S Hofman
Journal:  Cancer Imaging       Date:  2018-01-24       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.